GH1 and hyperinsulinemic hypoglycemia, familial, 4: The PREDICT study (NCT00256126; Merck Serono S.A., Study 24531: A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children Treated with SAIZEN®) was a month-long trial to identify the most responsive serum biomarkers associated with growth response to r-hGH therapy.